PRECAUTIONS SECTION.

PRECAUTIONS. Granisetron is not drug that stimulates gastric or intestinal peristalsis. It should not be used instead of nasogastric suction. The use of granisetron in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting may mask progressive ileus and/or gastric distention.An adequate QT assessment has not been conducted, but QT prolongation has been reported with granisetron. Therefore, granisetron should be used with caution in patients with pre-existing arrhythmias or cardiac conduction disorders, as this might lead to clinical consequences. Patients with cardiac disease, on cardio-toxic chemotherapy, with concomitant electrolyte abnormalities and/or on concomitant medications that prolong the QT interval are particularly at risk. Drug Interactions. Granisetron does not induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system in vitro. There have been no definitive drug-drug interaction studies to examine pharmacokinetic or pharmacodynamic interaction with other drugs; however, in humans, granisetron injection has been safely administered with drugs representing benzodiazepines, neuroleptics, and anti-ulcer medications commonly prescribed with antiemetic treatments. Granisetron injection also does not appear to interact with emetogenic cancer chemotherapies. Because granisetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of granisetron. No specific interaction studies have been conducted in anesthetized patients. In addition, the activity of the cytochrome P-450 subfamily 3A4 (involved in the metabolism of some of the main narcotic analgesic agents) is not modified by granisetron in vitro.In in vitro human microsomal studies, ketoconazole inhibited ring oxidation of granisetron. However, the clinical significance of in vivo pharmacokinetic interactions with ketoconazole is not known. In human pharmacokinetic study, hepatic enzyme induction with phenobarbital resulted in 25% increase in total plasma clearance of intravenous granisetron. The clinical significance of this change is not known.QT prolongation has been reported with granisetron. Use of granisetron in patients concurrently treated with drugs known to prolong the QT interval and/or are arrhythmogenic, this may result in clinical consequences. Serotonin syndrome (including altered mental status, autonomic instability, and neuromuscular symptoms) has been described following the concomitant use of 5-HT3 receptor antagonists and other serotonergic drugs, including selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) (see WARNINGS).. Carcinogenesis, Mutagenesis, Impairment of Fertility. In 24-month carcinogenicity study, rats were treated orally with granisetron 1, or 50 mg/kg/day (6, 30 or 300 mg/m2/day). The 50 mg/kg/day dose was reduced to 25 mg/kg/day (150 mg/m2/day) during week 59 due to toxicity. For 50 kg person of average height (1.46 m2 body surface area), these doses represent 4, 20, and 101 times the recommended clinical dose (1.48 mg/m2, oral) on body surface area basis. There was statistically significant increase in the incidence of hepatocellular carcinomas and adenomas in males treated with mg/kg/day (30 mg/m2/day, 20 times the recommended human dose based on body surface area) and above, and in females treated with 25 mg/kg/day (150 mg/m2/day, 101 times the recommended human dose based on body surface area). No increase in liver tumors was observed at dose of mg/kg/day (6 mg/m2/day, times the recommended human dose based on body surface area) in males and mg/kg/day (30 mg/m2/day, 20 times the recommended human dose based on body surface area) in females. In 12-month oral toxicity study, treatment with granisetron 100 mg/kg/day (600 mg/m2/day, 405 times the recommended human dose based on body surface area) produced hepatocellular adenomas in male and female rats while no such tumors were found in the control rats. 24-month mouse carcinogenicity study of granisetron did not show statistically significant increase in tumor incidence, but the study was not conclusive.Because of the tumor findings in rat studies, granisetron hydrochloride should be prescribed only at the dose and for the indication recommended (see INDICATIONS AND USAGE and DOSAGE AND ADMINISTRATION).Granisetron was not mutagenic in in vitro Ames test and mouse lymphoma cell forward mutation assay, and in vivo mouse micronucleus test and in vitro and ex vivo rat hepatocyte UDS assays. It, however, produced significant increase in UDS in HeLa cells in vitro and significant increased incidence of cells with polyploidy in an in vitro human lymphocyte chromosomal aberration test.Granisetron at oral doses up to 100 mg/kg/day (600 mg/m2/day, 405 times the recommended human dose based on body surface area) was found to have no effect on fertility and reproductive performance of male and female rats.. Pregnancy. Teratogenic EffectsPregnancy Category B: Reproduction studies have been performed in pregnant rats at oral doses up to 125 mg/kg/day (750 mg/m2/day, 507 times the recommended human dose based on body surface area) and pregnant rabbits at oral doses up to 32 mg/kg/day (378 mg/m2/day, 255 times the recommended human dose based on body surface area) and have revealed no evidence of impaired fertility or harm to the fetus due to granisetron. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Nursing Mothers. It is not known whether granisetron is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when granisetron is administered to nursing woman.. Pediatric Use. Safety and effectiveness in pediatric patients have not been established.. Geriatric Use. During clinical trials, 325 patients 65 years of age or older received granisetron tablets; 298 were 65 to 74 years of age, and 27 were 75 years of age or older. Efficacy and safety were maintained with increasing age.

ADVERSE REACTIONS SECTION.

ADVERSE REACTIONS. QT prolongation has been reported with granisetron (see PRECAUTIONS and Drug Interactions). Chemotherapy-Induced Nausea and VomitingOver 3700 patients have received granisetron tablets in clinical trials with emetogenic cancer therapies consisting primarily of cyclophosphamide or cisplatin regimens.In patients receiving granisetron tablets mg bid for 1, or 14 days, or mg daily for day, adverse experiences reported in more than 5% of the patients with comparator and placebo incidences are listed in Table 4.Table 4: Principal Adverse Events in Clinical TrialsPercent of Patients with EventGranisetron Hydrochloride TabletsAdverse events were recorded for days when granisetron tablets were give on single day and for up to 28 days when granisetron tablets were administered for or 14 days. mg twice day (N=978)Granisetron Hydrochloride Tablets mg once day (N=1450)ComparatorMetoclopramide/dexamethasone; phenothiazines/dexamethasone; dexamethasone alone; prochlorperazine. (N=599)Placebo (N=185)HeadacheUsually mild to moderate in severity. 21%20%13%12%Constipation18%14%16%8%Asthenia14%18%10%4%Diarrhea8%9%10%4%Abdominal Pain6%4%6%3%Dyspepsia4%6%5%4%Other adverse events reported in clinical trials were:Gastrointestinal: In single-day dosing studies in which adverse events were collected for days, nausea (20%) and vomiting (12%) were recorded as adverse events after the 24-hour efficacy assessment period.Hepatic: In comparative trials, elevation of AST and ALT (>2 times the upper limit of normal) following the administration of granisetron tablets occurred in 5% and 6% of patients, respectively. These frequencies were not significantly different from those seen with comparators (AST: 2%; ALT: 9%).Cardiovascular: Hypertension (1%); hypotension, angina pectoris, atrial fibrillation, and syncope have been observed rarely.Central Nervous System: Dizziness (5%), insomnia (5%), anxiety (2%), somnolence (1%). One case compatible with, but not diagnostic of, extrapyramidal symptoms has been reported in patient treated with granisetron tablets.Hypersensitivity: Rare cases of hypersensitivity reactions, sometimes severe (eg, anaphylaxis, shortness of breath, hypotension, urticaria) have been reported.Other: Fever (5%). Events often associated with chemotherapy also have been reported: leukopenia (9%), decreased appetite (6%), anemia (4%), alopecia (3%), thrombocytopenia (2%).Over 5000 patients have received injectable granisetron in clinical trials.Table gives the comparative frequencies of the five commonly reported adverse events (>=3%) in patients receiving granisetron injection, 40 mcg/kg, in single-day chemotherapy trials. These patients received chemotherapy, primarily cisplatin, and intravenous fluids during the 24-hour period following granisetron injection administration.Table 5: Principal Adverse Events in Clinical Trials Single-Day ChemotherapyPercent of Patients with EventGranisetron Hydrochloride InjectionAdverse events were generally recorded over days post-granisetron injection administration.40 mcg/kg (N=1268)ComparatorMetoclopramide/dexamethasone and phenothiazines/dexamethasone. (N=422)Headache14%6%Asthenia5%6%Somnolence4%15%Diarrhea4%6%Constipation3%3%In the absence of placebo group, there is uncertainty as to how many of these events should be attributed to granisetron, except for headache, which was clearly more frequent than in comparison groups.Radiation-Induced Nausea and VomitingIn controlled clinical trials, the adverse events reported by patients receiving granisetron tablets and concurrent radiation were similar to those reported by patients receiving granisetron tablets prior to chemotherapy. The most frequently reported adverse events were diarrhea, asthenia, and constipation. Headache, however, was less prevalent in this patient population.Postmarketing Experience QT prolongation has been reported with granisetron (see PRECAUTIONS and Drug Interactions).

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION.

Carcinogenesis, Mutagenesis, Impairment of Fertility. In 24-month carcinogenicity study, rats were treated orally with granisetron 1, or 50 mg/kg/day (6, 30 or 300 mg/m2/day). The 50 mg/kg/day dose was reduced to 25 mg/kg/day (150 mg/m2/day) during week 59 due to toxicity. For 50 kg person of average height (1.46 m2 body surface area), these doses represent 4, 20, and 101 times the recommended clinical dose (1.48 mg/m2, oral) on body surface area basis. There was statistically significant increase in the incidence of hepatocellular carcinomas and adenomas in males treated with mg/kg/day (30 mg/m2/day, 20 times the recommended human dose based on body surface area) and above, and in females treated with 25 mg/kg/day (150 mg/m2/day, 101 times the recommended human dose based on body surface area). No increase in liver tumors was observed at dose of mg/kg/day (6 mg/m2/day, times the recommended human dose based on body surface area) in males and mg/kg/day (30 mg/m2/day, 20 times the recommended human dose based on body surface area) in females. In 12-month oral toxicity study, treatment with granisetron 100 mg/kg/day (600 mg/m2/day, 405 times the recommended human dose based on body surface area) produced hepatocellular adenomas in male and female rats while no such tumors were found in the control rats. 24-month mouse carcinogenicity study of granisetron did not show statistically significant increase in tumor incidence, but the study was not conclusive.Because of the tumor findings in rat studies, granisetron hydrochloride should be prescribed only at the dose and for the indication recommended (see INDICATIONS AND USAGE and DOSAGE AND ADMINISTRATION).Granisetron was not mutagenic in in vitro Ames test and mouse lymphoma cell forward mutation assay, and in vivo mouse micronucleus test and in vitro and ex vivo rat hepatocyte UDS assays. It, however, produced significant increase in UDS in HeLa cells in vitro and significant increased incidence of cells with polyploidy in an in vitro human lymphocyte chromosomal aberration test.Granisetron at oral doses up to 100 mg/kg/day (600 mg/m2/day, 405 times the recommended human dose based on body surface area) was found to have no effect on fertility and reproductive performance of male and female rats.

CLINICAL PHARMACOLOGY SECTION.

CLINICAL PHARMACOLOGY. Granisetron is selective 5-hydroxytryptamine3 (5-HT3) receptor antagonist with little or no affinity for other serotonin receptors, including 5-HT1; 5-HT1A; 5-HT1B/C; 5-HT2; for alpha1-, alpha2-, or beta-adrenoreceptors; for dopamine-D2; or for histamine-H1; benzodiazepine; picrotoxin or opioid receptors.Serotonin receptors of the 5-HT3 type are located peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. During chemotherapy that induces vomiting, mucosal enterochromaffin cells release serotonin, which stimulates 5-HT3 receptors. This evokes vagal afferent discharge, inducing vomiting. Animal studies demonstrate that, in binding to 5-HT3 receptors, granisetron blocks serotonin stimulation and subsequent vomiting after emetogenic stimuli such as cisplatin. In the ferret animal model, single granisetron injection prevented vomiting due to high-dose cisplatin or arrested vomiting within to 30 seconds.In most human studies, granisetron has had little effect on blood pressure, heart rate or ECG. No evidence of an effect on plasma prolactin or aldosterone concentrations has been found in other studies.Following single and multiple oral doses, granisetron hydrochloride tablets slowed colonic transit in normal volunteers. However, granisetron had no effect on oro-cecal transit time in normal volunteers when given as single intravenous (IV) infusion of 50 mcg/kg or 200 mcg/kg.PharmacokineticsIn healthy volunteers and adult cancer patients undergoing chemotherapy, administration of granisetron tablets produced mean pharmacokinetic data shown in Table 1.Table 1: Pharmacokinetic Parameters (Median [range]) Following Granisetron Hydrochloride Tablets USPPeak Plasma Concentration (ng/mL)Terminal Phase Plasma Half-Life (h)Volume of Distribution (L/kg)Total Clearance (L/h/kg)Cancer Patients1 mg bid, days (N=27)5.99[0.63 to 30.9]N.D.Not determined after oral administration; following single intravenous dose of 40 mcg/kg, terminal phase half-life was determined to be 8.95 hours. N.D. 0.52[0.09 to 7.37]Volunteers single mg dose (N=39)3.63[0.27 to 9.14]6.23[0.96 to 19.9]3.94 [1.89 to 39.4]0.41[0.11 to 24.6]AbsorptionWhen granisetron tablets were administered with food, AUC was decreased by 5% and Cmax increased by 30% in non-fasted healthy volunteers who received single dose of 10 mg.DistributionPlasma protein binding is approximately 65% and granisetron distributes freely between plasma and red blood cells.MetabolismGranisetron metabolism involves N-demethylation and aromatic ring oxidation followed by conjugation. In vitro liver microsomal studies show that granisetrons major route of metabolism is inhibited by ketoconazole, suggestive of metabolism mediated by the cytochrome P-450 3A subfamily. Animal studies suggest that some of the metabolites may also have 5-HT3 receptor antagonist activity.EliminationClearance is predominantly by hepatic metabolism. In normal volunteers, approximately 11% of the orally administered dose is eliminated unchanged in the urine in 48 hours. The remainder of the dose is excreted as metabolites, 48% in the urine and 38% in the feces.SubpopulationsGenderThe effects of gender on the pharmacokinetics of granisetron tablets have not been studied. However, after intravenous infusion of granisetron, no difference in mean AUC was found between males and females, although males had higher Cmax generally.In elderly and pediatric patients and in patients with renal failure or hepatic impairment, the pharmacokinetics of granisetron was determined following administration of intravenous granisetron.ElderlyThe ranges of the pharmacokinetic parameters in elderly volunteers (mean age 71 years), given single 40 mcg/kg intravenous dose of granisetron injection, were generally similar to those in younger healthy volunteers; mean values were lower for clearance and longer for half-life in the elderly.Renal Failure PatientsTotal clearance of granisetron was not affected in patients with severe renal failure who received single 40 mcg/kg intravenous dose of granisetron injection.Hepatically Impaired PatientsA pharmacokinetic study with intravenous granisetron in patients with hepatic impairment due to neoplastic liver involvement showed that total clearance was approximately halved compared to patients without hepatic impairment. Given the wide variability in pharmacokinetic parameters noted in patients, dosage adjustment in patients with hepatic functional impairment is not necessary.Pediatric PatientsA pharmacokinetic study in pediatric cancer patients (2 to 16 years of age), given single 40 mcg/kg intravenous dose of granisetron injection, showed that volume of distribution and total clearance increased with age. No relationship with age was observed for peak plasma concentration or terminal phase plasma half-life. When volume of distribution and total clearance are adjusted for body weight, the pharmacokinetics of granisetron are similar in pediatric and adult cancer patients.

DRUG INTERACTIONS SECTION.

Drug Interactions. Granisetron does not induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system in vitro. There have been no definitive drug-drug interaction studies to examine pharmacokinetic or pharmacodynamic interaction with other drugs; however, in humans, granisetron injection has been safely administered with drugs representing benzodiazepines, neuroleptics, and anti-ulcer medications commonly prescribed with antiemetic treatments. Granisetron injection also does not appear to interact with emetogenic cancer chemotherapies. Because granisetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of granisetron. No specific interaction studies have been conducted in anesthetized patients. In addition, the activity of the cytochrome P-450 subfamily 3A4 (involved in the metabolism of some of the main narcotic analgesic agents) is not modified by granisetron in vitro.In in vitro human microsomal studies, ketoconazole inhibited ring oxidation of granisetron. However, the clinical significance of in vivo pharmacokinetic interactions with ketoconazole is not known. In human pharmacokinetic study, hepatic enzyme induction with phenobarbital resulted in 25% increase in total plasma clearance of intravenous granisetron. The clinical significance of this change is not known.QT prolongation has been reported with granisetron. Use of granisetron in patients concurrently treated with drugs known to prolong the QT interval and/or are arrhythmogenic, this may result in clinical consequences. Serotonin syndrome (including altered mental status, autonomic instability, and neuromuscular symptoms) has been described following the concomitant use of 5-HT3 receptor antagonists and other serotonergic drugs, including selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) (see WARNINGS).

SPL UNCLASSIFIED SECTION.

CLINICAL TRIALS. Chemotherapy-Induced Nausea and VomitingGranisetron tablets prevent nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, as shown by 24-hour efficacy data from studies using both moderately- and highly-emetogenic chemotherapy.Moderately Emetogenic ChemotherapyThe first trial compared granisetron tablets doses of 0.25 mg to mg twice day, in 930 cancer patients receiving, principally, cyclophosphamide, carboplatin, and cisplatin (20 mg/m2 to 50 mg/m2). Efficacy was based on complete response (ie, no vomiting, no moderate or severe nausea, no rescue medication), no vomiting, and no nausea. Table summarizes the results of this study.Table 2: Prevention of Nausea and Vomiting 24 Hours Post-ChemotherapyChemotherapy included oral and injectable cyclophosphamide, carboplatin, cisplatin (20 mg/m2 to 50 mg/m2), dacarbazine, doxorubicin, epirubicin. Percentages of PatientsGranisetron Tablet DoseEfficacy Measures0.25 mg twice day (N=229) %0.5 mg twice day (N=235) %1 mg twice day (N=233) %2 mg twice day (N=233) %Complete ResponseNo vomiting, no moderate or severe nausea, no rescue medication. 6170Statistically significant (p<0.01) vs. 0.25 mg bid. 81, Statistically significant (p<0.01) vs. 0.5 mg bid. 72 No Vomiting6677 88 79 No Nausea485763 54Results from second double-blind, randomized trial evaluating granisetron tablets mg once day and granisetron tablets mg twice day were compared to prochlorperazine 10 mg twice day derived from historical control. At 24 hours, there was no statistically significant difference in efficacy between the two granisetron tablet regimens. Both regimens were statistically superior to the prochlorperazine control regimen (see Table 3).Table 3: Prevention of Nausea and Vomiting 24 Hours Post-ChemotherapyModerately emetogenic chemotherapeutic agents included cisplatin (20 mg/m2 to 50 mg/m2), oral and intravenous cyclophosphamide, carboplatin, dacarbazine, doxorubicin. Percentages of PatientsEfficacy MeasuresGranisetron Hydrochloride Tablets mg twice day (N=354) %Granisetron Hydrochloride Tablets mg once day (N=343) %ProchlorperazineHistorical control from previous double-blind granisetron trial.10 mg twice daily (N=111) %Complete ResponseNo vomiting, no moderate or severe nausea, no rescue medication. 69Statistically significant (p<0.05) vs. prochlorperazine historical control. 64 41No Vomiting82 77 48No Nausea51 53 35Total ControlNo vomiting, no nausea, no rescue medication. 51 50 33Results from granisetron tablets mg daily alone treatment arm in third double-blind, randomized trial, were compared to prochlorperazine (PCPZ), 10 mg bid, derived from historical control. The 24-hour results for granisetron tablets mg daily were statistically superior to PCPZ for all efficacy parameters: complete response (58%), no vomiting (79%), no nausea (51%), total control (49%). The PCPZ rates are shown in Table 3.Cisplatin-Based ChemotherapyThe first double-blind trial compared granisetron tablets mg bid, relative to placebo (historical control), in 119 cancer patients receiving high-dose cisplatin (mean dose 80 mg/m2). At 24 hours, granisetron tablets mg bid was significantly (p<0.001) superior to placebo (historical control) in all efficacy parameters: complete response (52%), no vomiting (56%) and no nausea (45%). The placebo rates were 7%, 14%, and 7%, respectively, for the three efficacy parameters.Results from granisetron tablets mg once day alone treatment arm in second double-blind, randomized trial, were compared to both granisetron tablets mg twice day and placebo historical controls. The 24-hour results for granisetron tablets mg once day were: complete response (44%), no vomiting (58%), no nausea (46%), total control (40%). The efficacy of granisetron tablets mg once day was comparable to granisetron tablets mg twice day and statistically superior to placebo. The placebo rates were 7%, 14%, 7%, and 7%, respectively, for the four parameters.No controlled study comparing granisetron injection with the oral formulation to prevent chemotherapy-induced nausea and vomiting has been performed.Radiation-Induced Nausea and VomitingTotal Body IrradiationIn double-blind randomized study, 18 patients receiving granisetron tablets, mg daily, experienced significantly greater antiemetic protection compared to patients in historical negative control group who received conventional (non-5-HT3 antagonist) antiemetics. Total body irradiation consisted of 11 fractions of 120 cGy administered over days, with three fractions on each of the first days, and two fractions on the fourth day. Granisetron tablets were given one hour before the first radiation fraction of each day.Twenty-two percent (22%) of patients treated with granisetron tablets did not experience vomiting or receive rescue antiemetics over the entire 4-day dosing period, compared to 0% of patients in the historical negative control group (p<0.01).In addition, patients who received granisetron tablets also experienced significantly fewer emetic episodes during the first day of radiation and over the 4-day treatment period, compared to patients in the historical negative control group. The median time to first emetic episode was 36 hours for patients who received granisetron tablets.Fractionated Abdominal RadiationThe efficacy of granisetron tablets, mg daily, was evaluated in double-blind, placebo-controlled randomized trial of 260 patients. Granisetron tablets were given hour before radiation, composed of up to 20 daily fractions of 180 to 300 cGy each. The exceptions were patients with seminoma or those receiving whole abdomen irradiation who initially received 150 cGy per fraction. Radiation was administered to the upper abdomen with field size of at least 100 cm2.The proportion of patients without emesis and those without nausea for granisetron tablets, compared to placebo, was statistically significant (p<0.0001) at 24 hours after radiation, irrespective of the radiation dose. Granisetron was superior to placebo in patients receiving up to 10 daily fractions of radiation, but was not superior to placebo in patients receiving 20 fractions.Patients treated with granisetron tablets (N=134) had significantly longer time to the first episode of vomiting (35 days vs. days, p<0.001) relative to those patients who received placebo (N=126), and significantly longer time to the first episode of nausea (11 days vs. day, p<0.001). Granisetron provided significantly greater protection from nausea and vomiting than placebo.

WARNINGS SECTION.

WARNINGS. Serotonin SyndromeThe development of serotonin syndrome has been reported with 5-HT3 receptor antagonists. Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue). Some of the reported cases were fatal. Serotonin syndrome occurring with overdose of another 5-HT3 receptor antagoinist alone has also been reported. The majority of reports of serotonin syndrome related to 5-HT3 receptor antagonist use occurred in post-anesthesia care unit or an infusion center. Symptoms associated with serotonin syndrome may include the following combination of signs and symptoms: mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, with or without gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of granisetron and other serotonergic drugs. If symptoms of serotonin syndrome occur, discontinue granisetron and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if granisetron is used concomitantly with other serotonergic drugs (see Drug Interactions and Patient Counseling Information).